News | December 21, 2024
Lonza expands capsule manufacturing capacity in India and China
New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari and Suzhou
New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari and Suzhou
This facility marks a significant milestone in transforming the global food industr
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate
CLL is one of the most common leukemias among adults affecting more than 200,000 people in the US
Despite NTC014, due to its simplified therapeutic regimen, has been administered at a lower posology than the antibiotic comparator
First GMP batch released at Lonza’s next-generation mammalian manufacturing facility in Portsmouth (US)
If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
This agreement reinforces Lubrizol’s commitment to Make-In-India and broadens a previously committed US$ 350 million investment to support local manufacturing
Subscribe To Our Newsletter & Stay Updated
